期刊文献+

^(169)Yb粒子源瘤内植入治疗荷胶瘤裸鼠 被引量:2

^(169)Yb seed brachytherapy for treatment of tumor in athymic mice
暂未订购
导出
摘要 目的:观察169Yb粒子源瘤内植入法对肿瘤内照射的治疗效果,并了解粒子源数量对治疗效果的影响,同时与125I进行比较。方法:实验于2006-05/11在解放军总医院核医学科实验室完成。①采用Hela细胞体外培养,169Yb和125I(由中国原子能研究院同位素所提供)分别置入培养液中照射细胞,观察射线对细胞杀伤范围。②采用胶瘤细胞接种到裸鼠右腋下,建立肿瘤模型,将40只荷瘤鼠随机分成4组,每组10只。二粒子源植入组瘤内种入2粒169Yb(每粒活度为92.5MBq),五粒子源植入组种入5粒169Yb,125I粒子源植入组植入2粒125I(每粒活度为18.5MBq),对照组不植入粒子。③将粒子源用植入针植入裸鼠右腋下肿瘤内,观察植入前、后裸鼠肿瘤大小,记录裸鼠死亡时间。第60天处死所有裸鼠,组织切片病理检查进一步验证肿瘤的发生和消退情况。对照组和二粒子源植入组荷瘤鼠处死前取血,测血象和血生化。结果:①169Yb粒子源在体外对Hela细胞杀伤明显,杀伤范围是粒子直径的两三倍,其杀伤范围大于125I粒子源。②五粒子源植入组鼠于粒子源植入第11天全部死亡;二粒子源植入组鼠在粒子源植入第60天后肿瘤仅有原来的38%,肿瘤消退率高于对照组和125I粒子源植入组(P<0.05)。③对照组和二粒子源植入组血象指标和生化指标无明显差异。结论:①169Yb在体外能有效抑制肿瘤细胞的生长,其杀伤范围明显大于125I粒子源。②植入2粒169Yb粒子源对肿瘤有明显的治疗作用,且比较安全,其效果优于125I。 AIM: To observe the curative effects of ^169Yb seeds brachytherapy on tumor, so as to explore the influence of seed dose on the curative effect and compare it with ^125I. METHODS: From May to November 2006, the experiment was performed at laboratory of Department of Nuclear Medicine, General Hospital of Chinese PLA. (1)Hela cells were cultured in vitro and exposed to radiation from ^169Yb and ^125I seeds (provided by Department of Isotopes, China Institute of Atomic Energy) which were put into the culture solution respectively to observe the killing range of the radiation. (2)Tumor cells were transplanted into the right armpit of athymic mouse to establish the tumor models. Forty mice with tumor were randomly divided into four groups with 10 in each group: Two groups were given 2 seeds and 5 seeds implantation of ^169Yb (each seed was 92.5 MBq), respectively; the third group was given 2 seeds implantation of ^125I (each seed was 18.5 MBq); the fourth group as control was not treated. (3)The seeds were implanted into the right subaxillary tumor of mice by graft needle. Tumor size was measured before and after seed implantation and the dead time of mice were recorded. On day 60, all the mice were sacrificed to identify tumor growth and extinction by histopathology. The blood of the control group and two seeds group were harvested before the mice were killed to measure the hemogram and biochemical indexes. RESULTS: (1)^169Yb seeds could kill the Hela tumor cells in vitro. The kilting range was two to three times of the seed's diameter, which was larger than that of ^125I. (2)All the mice of the five seeds group died on day 11 after seed implantation; the tumor size 60 days later was only 38% of the former with higher tumor remission rate than the control group and ^125I seed groups (P 〈 0.05). (3)There were no obvious difference in the hemogram and biochemical indexes between the control group and two seeds implantation group. CONCLUSION: (1) ^169Yb seeds could effectively inhibit the growth of tumor cells in vitro, and the killing effect is significantly larger than that of ^125I seed. (2)Brachytherapy with two ^169Yb seeds displays a better curative effect, which is superior to that of ^125I.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2007年第16期3043-3046,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献20

二级参考文献59

  • 1张雪哲,吴沛宏,张福君.开展放射性粒子组织间植入治疗恶性肿瘤[J].中华放射学杂志,2004,38(9):901-902. 被引量:31
  • 2胡效坤,王明友,杨志国,邱春东,吕东方,李晓东,左太阳.CT导引下经皮穿刺组织间植入^(125)I放射微粒子治疗中心型肺癌的应用研究[J].中华放射学杂志,2004,38(9):910-915. 被引量:116
  • 3黄振国,张雪哲,王武,洛小林,王继英.CT导引下^(125)I粒子植入在治疗恶性肿瘤中的应用[J].中华放射学杂志,2004,38(9):921-925. 被引量:135
  • 4黎功 王俊杰 唐劲天 黎功.放射性粒子近距离治疗腹部肿瘤[A].王俊杰,唐劲天,黎功.放射性粒子近距离治疗肿瘤[C].北京:北京医科大学出版社,2001.123-133.
  • 5Zelefsky MY, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent Ⅰ-125 prostate implantation for patients with localized prostate cancer [ J ]. Int J Radiat Oncol Biol Phys,2000,47(8) : 1261-1266.
  • 6Lee W,Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of Ⅰ-125 brachytherapy seeds[J]. Ann Thorac Surg,2003,75(2) :237-243.
  • 7Older RA, Synder B, Krupaki TL, et al. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytheray[ J] .J Urol ,2001, 165(11) : 1590-1592.
  • 8Hakenberg OW, Wirth MP, Hermann T, et al. Recommendations for the treament of localized prostate cancer by permanent interstitial brachytherapy(Review) [ J]. Urol Int, 2003,70( 1 ) : 15-20.
  • 9Molloy JA, Williams MB. Treatment planning consideration and quality assurance for CT-guide transischiorectal implantation of the prostate[J] .Med Phys, 1999.26(12) :1943-1951.
  • 10Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver[J]. Cancer, 1999,85(10) : 1218-1225.

共引文献122

同被引文献26

  • 1岳麓,程文英,罗伟华,陈红红,刘伟琪.^(125)I籽源离体照射细胞平面剂量率分布研究[J].中华放射肿瘤学杂志,2005,14(5):435-438. 被引量:9
  • 2王俊杰,冉维强,袁惠书,姜玉良,刘江平,李金娜,姜伟娟.放射性^(125)I粒子植入治疗头颈部肿瘤[J].中华放射医学与防护杂志,2006,26(1):23-26. 被引量:37
  • 3苑淑渝,王道平,戴光复,何培坤,刘强.放射性^(125)I粒籽源的剂量分布[J].中华放射医学与防护杂志,2006,26(6):607-608. 被引量:9
  • 4Krug B, Crott R, De Canniere L. A systematic review of the predictive value of 18F-fluoro-2-deoxyglucose positron emission tomography on survival in locally advanced rectal cancer after neoadjuvant chemoradiation [J]. Colorectal Dis, 2013, 15(11):e627-633.
  • 5Hutchings M. FDG-PET Response-adapted Therapy: Is 18F-Fluorodeoxyglucose Positron Emission Tomography a Safe Predictor for a Change of Therapy? [J]. Hematol Oncol Clin North Am, 2014, 28(1):87-103.
  • 6Trnad AR, Fritscher T, Cavallaro A, et al. FDG PET/CT in head and neck brachytherapy [J]. Braehytherapy, 2008, 7:165.
  • 7Orker W, Herholz K, Voges J, et al. Glucose consumption and methionine uptakein low-grade gliomas after iodine-125 brachytherapy[J]. Eur J Nucl Med, 1996, 23(5):583-586.
  • 8Voges J, Herholz K, Holzer T, et al. HC-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds [J]. Stereotact Funct Neurosurg, 1997, 69(2): 129-135.
  • 9Gebhart G, Gamez C, Holmes E, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO [J]. J Nucl Med, 2013, 54(11):1862-1868.
  • 10Krug B, Crott R, De Canniere L, et al. A systematic review of the predictive value of 18F-fluoro-2-deoxyglucose positron emission tomography on survival in locally advanced rectal cancer after neoadjuvant chemoradiation[J]. Colorectal Dis, 2013, 15(11): e627-633.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部